key: cord-0751723-2oqwodg6
authors: Martin, Archer Kilbourne; Shah, Sadia Z.; Guru, Pramod; Chaudhary, Sanjay; Franco, Pablo Moreno; Makey, Ian; Fritz, Ashley Virginia; Pham, Si M.; Thomas, Mathew
title: Multidisciplinary Approach for Lung Transplantation due to COVID-19
date: 2022-03-09
journal: Mayo Clin Proc Innov Qual Outcomes
DOI: 10.1016/j.mayocpiqo.2022.02.003
sha: da5d9d9fd098b72953941f2fde633e8cc53e26de
doc_id: 751723
cord_uid: 2oqwodg6

Coronavirus disease 2019 (COVID-19), a novel etiology of end-stage lung disease, has resulted in major disruptions to the process of health care delivery worldwide. These disruptions have led to team-based innovations globally, resulting in a broad range of new processes in cardiopulmonary perioperative management. A key intersection of multidisciplinary teamwork and COVID-19 is found in lung transplantation, where diverse teams collaborate throughout the perioperative period to achieve optimal outcomes. In this manuscript, we describe the multidisciplinary approach taken by Mayo Clinic Florida to manage COVID-19 patients presenting for lung transplantation.

Coronavirus disease 2019 (COVID- 19) , a novel etiology of end-stage lung disease (ESLD), has resulted in major disruptions to the process of health care delivery worldwide. 1 These disruptions have led to team-based innovations globally, resulting in a broad range of new processes impacting education, communication, and personal protective equipment (PPE) manufacturing. 1, 2 A key intersection of multidisciplinary teams and COVID-19 is found in lung transplantation, where diverse teams collaborate throughout the perioperative period to achieve optimal outcomes in patients with ESLD. 3, 4 The first major case series describing early outcomes in lung transplantation focused on the surgical considerations for COVID-19 as well as preliminary proposed criteria for pursuing transplantation in patients with COVID-19 related ESLD. 5 Since then, several other high volume centers have published their institutional experience in lung transplantation for COVID-19. 6, 7 While data on the total number of lung transplants for COVID-19 performed worldwide are lacking, a recent report noted at least 60 had been performed throughout North America and European centers. 8 Mayo Clinic Florida (MCF) has innovated a comprehensive multi-disciplinary communication and clinical pathway for lung transplantation for COVID-19 from initial evaluation of patients to be transferred to MCF for lung transplantation evaluation and consideration for extracorporeal membrane oxygenation (ECMO) placement to lung transplantation and perioperative management. In this paper, we will describe our team's process and its application in a series of 3 lung transplants performed for ESLD from COVID-19.

J o u r n a l P r e -p r o o f COVID-19 may lead to acute respiratory distress syndrome (ARDS) refractory to conventional therapy, requiring the use of ECMO to assist in decarboxylation and oxygenation. 9 Current guidelines from the extracorporeal life support organization (ELSO) note that while conventional selection criteria should be utilized for COVID-19 ECMO implementation, a key difference between COVID-19 and non-COVID-19 ECMO patients is the longer duration of ECMO required in COVID-19 ARDS patients. 9 Although MCF follows standard ELSO criteria for ECMO selection, we developed early multidisciplinary team (MDT) communication and clinical pathways for both inpatient ECMO utilization and transfers from outside hospitals ( Figures   1 and 2 ).

The MDT team members represent medical and ancillary support specialties, including cardiothoracic surgeons, cardiac anesthesiologists, intensivists, transplant pulmonologists, intensive care unit (ICU) nursing leads, ethics committee representatives, perfusionists, ECMO specialists and coordinators. Building upon a pre-existing cardiogenic shock communication pathway (Figure 3 ), the MDT added tiers of communication which are activated when an outside hospital COVID-19 transfer or utilization of ECMO is being considered. Upon activation of the pathway, which is disseminated via the internal hospital communication system to individual pagers, the MDT members arrive to a virtual internet meeting room to discuss the situation and decide the next steps. In addition to the appropriate indication for ECMO, the type of ECMO support required, veno-venous (VV), veno-arterial (VA), or veno-arterial-venous (VAV), and the resource availability (ECMO units, staffing and ICU bed) are also discussed. Unless cardiogenic shock is also present, VV ECMO is preferred in patients with isolated lung failure. If the patient is accepted for ECMO, each team member disseminates relative information to their respective J o u r n a l P r e -p r o o f organizational downline in a hub-and-spoke communication model. These downline personnel include social workers, financial managers, physical therapists, perfusionists, and operating room staff.

All ECMO cannulations in our institution are performed in the operating room. Prior to transferring the patient to the operating room, a pre-procedural MDT huddle discusses the logistics of COVID-19 ECMO placement, including safety practices for ICU-to-operating room transfer, individual staff PPE utilization, and ECMO cannulation imaging preferences, which mainly includes transesophageal echocardiography (TEE) while fluoroscopy is used as needed. 10, 11 Each of these logistical components is reviewed for team fluency, and video resources are immediately available to provide additional training review for high risk procedures such as correct PPE donning and doffing in COVID-19 patients.

Although VV ECMO cannulation can be performed in different configurations, our preferred approach is a combination of right femoral venous drainage with right internal jugular return cannulae. This configuration decreases the challenges of mobility with bifemoral cannulation and the potential for misdirection or malposition associated with the single doublelumen cannula via right internal jugular approach. After ECMO is initiated, the patient is brought back to a dedicated cardiovascular and thoracic transplant (CVTx) ICU.

Management of COVID-19 patients remains a challenge given the novelty of the disease.

Despite having an established and well-functioning ECMO team for years, this novelty has necessitated institution of rapid adaptations to the management strategy in these patients. We J o u r n a l P r e -p r o o f employ a strategy of early percutaneous tracheostomy within the first week of cannulation in order to facilitate airway management, physiotherapy, and decrease the need for sedation and analgesia.

If the anatomy or body habitus are found to be not conducive for percutaneous tracheostomy in CVTx ICU, then we proceed with open tracheostomy in the OR. Ventilator settings are adjusted according to blood gas analysis with flexibility for both pressure and volume-controlled mode with the aim to protect the lungs. Our initial default settings are pressure control mode of ventilation with a rate of 10 breath/min, positive end expiratory pressure (PEEP) of 10 centimeters of water (cm H2O), and inspiratory pressure of 10 cm H2O and fraction of inspired oxygen (FiO2) of 40% to 70% when the patients are heavily sedated. The mode of ventilator is switched to pressure support when the patient is awake.

Bivalirudin is the preferred anticoagulation used by our team for most of our patients, with goal activated partial thromboplastin time (aPTT) value between 60-80 seconds. Multi-modal analgesia and sedation pathways using opioids, propofol, benzodiazepines, and dexmedetomidine are initiated and transitioned from continuous intravenous to enteral route as the clinical status allows. Our published physiotherapy findings in ECMO patients note the importance of aggressive early mobilization in COVID-19 ECMO patients 12 , and data also support the need for specific vigilance regarding hematological complications in patients on ECMO secondary to If the patient is deemed to be a potential candidate for lung transplant, the pulmonary transplant team is consulted earlier in the course to initiate transplant work up.

Prior to considering patients with COVID-19 for lung transplantation, guidelines for for lung transplantation. We have added our experience to those points which are listed below:

• Basic guidelines for lung transplant listing are followed in all cases.

• Age: Patients <55 years old are preferred but patients <65 years of age can be considered • Time to recover from ARDS related to COVID-19 (CARDS) can be weeks to months in some cases. We have allowed months in certain cases with discharge of these patients to home or rehabilitation facilities. In other cases where the risk of mortality is high, such as patients on high ECMO settings with progressive clinical decline, they can be considered for transplant listing sooner if they are not in acute infectious phase of their disease.

• Patients being considered for lung transplant listing need to be awake and able to participate in the discussion of transplant. Since most of these patients may be on narcotics, anxiolytics and/or sedatives, especially those on mechanical ventilation and ECMO, it is important to also seek consent from care givers in these cases. Patients whose neurological status cannot be determined are not considered candidates for transplant evaluation. It is important to recognize potential underlying depression, posttraumatic stress disorder and anxiety in these patients as these disorders can complicate their clinical progress and ability to participate in rehabilitation. 17 • Rehabilitation potential is the key when assessing these patients for transplantation. A we routinely utilized the existing configuration in other lung transplant patients who were already on peripheral VA ECMO. Intraoperatively, we use a novel hybrid VA ECMO circuit that we previously reported. 18, 19 To date, we have used this circuit on over 125 lung transplantations, and all COVID-19 patients were transplanted utilizing this novel ECMO circuit. After the lungs are implanted, we determine the need for postoperative ECMO prolongation based on published criteria to assess graft function. 20 Postoperative plans are tailored to ongoing use of ECMO for stabilization, and both early regional anesthetic techniques as well as early physiotherapy mobilization are foundational goals for our ICU recovery.

Our approach is grounded in early engagement of the lung transplant MDT to facilitate communication regarding the complexities of approaching transplantation in COVID-19 patients.

To date, we have performed 3 bilateral lung transplantations for patients with COVID-19 which are discussed below.

A male in his early 50's with past medical history of hypertension and type 2 diabetes mellitus (A1c 12%) presented to the emergency room in respiratory distress 1 week after initial 

A male in his mid-50's with past medical history of gout was transferred from an outside hospital for consideration of VV ECMO. Co-morbidities included limited rehabilitation potential, pre-existing pressure injuries, gastrointestinal bleeding, and right ventricular dysfunction with mild pulmonary hypertension. He underwent VV ECMO via a right femoral and right internal jugular approaches, and a comprehensive ICU therapy was initiated for his co-morbidities. During lung transplantation workup, he was noted to have significant disease in his left anterior descending and circumflex arteries and was listed for combined lung transplant and 2-vessel coronary artery bypass grafting (CABG). The ECMO configuration was converted to VA ECMO for lung implantation. Once implantation was complete, we utilized the hybrid VA ECMO circuit to convert to cardiopulmonary bypass and performed a 2-vessel CABG with saphenous vein to the J o u r n a l P r e -p r o o f left anterior descending and obtuse marginal arteries. He was transitioned back to VV ECMO and transferred to the ICU where continuous renal replacement therapy (CRRT) had to be initiated for volume management. Both ECMO and CRRT were discontinued on POD #8, and the patient was discharged on POD #143 due to significant physiotherapy requirements. He had excellent graft function on last evaluation.

A male in his early 50's with no significant past medical history underwent a course of VV ECMO for 79 days at an outside hospital. He was discharged to long term care facility on mechanical ventilation after ECMO was discontinued. During this initial hospitalization, he had multiple co-morbidities including deep venous thromboses, gastrointestinal bleeding, multi-drug resistant pneumonia, and two cardiac arrests. He was admitted to MCF for consideration of lung transplantation evaluation because of failure to wean off mechanical ventilation. Echocardiogram revealed severely enlarged and dysfunctional right ventricle. Cardiac catheterization showed mild pulmonary hypertension and severe right coronary artery disease. We recommended and proceeded with right coronary artery percutaneous intervention, with subsequent lung transplantation listing 1 month after completion of dual anti-platelet therapy. Intraoperative support for bilateral lung transplantation was provided via hybrid VA ECMO, which was discontinued successfully at the end of the procedure. Although he developed PGD grade 1 at 48 hours which resolved by 72 hours, he was discharged from the hospital and is doing well.

The intersection of COVID-19 and lung transplantation present opportunities for MDT clinical care and communication. COVID-19 is a novel disease and we as clinicians are still J o u r n a l P r e -p r o o f learning the clinical course of these patients. With a MDT approach, we have been able to learn when can we safely wait to allow the patients to recover from their COVID-19 related lung disease versus when a transplant is necessary. With time, our understanding of COVID-19 related lung disease progression has evolved leading to multiple patients being delisted from transplant waitlist for being too well who were initially evaluated and listed for lung transplant. Utilizing a combination of pre-COVID-19 systems such as cardiogenic shock tier communication, transplantation selection committee, and MDT perioperative transplant care, our growing experience has allowed us to hone our novel MDT approach to communication and clinical care in patients with COVID-19 presenting for lung transplantation. 

Innovation in Response to the COVID-19 Pandemic Crisis

Considerations and Cautions for Three-Dimensional-Printed Personal Protective Equipment in the COVID-19 Crisis. 3d Print Addit Manuf

Multidisciplinary collaboration: the key to advancing lung transplantation outcomes

Practical considerations for developing a lung transplantation anesthesiology program

Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries

Lung transplantation for coronavirus disease 2019 (COVID-19): The who, what, where, when, and why

Lung transplantation for acute COVID-19: the Toronto Lung Transplant Program experience

Commentary: Post-COVID-19 acute respiratory distress syndrome and post-COVID-19 fibrosis-the new kids in town

Extracorporeal Membrane Oxygenation for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization

Transthoracic Echocardiogram-Guided Avalon Catheter Repositioning

Successful Rescue Utilization of Intraoperative Tissue Plasminogen Activator in the Setting of Massive Thrombosis of Avalon Catheter and Patient in Extremis with Refractory Hypoxemia

Physical Therapy and Sedation While on Extracorporeal Membrane Oxygenation for COVID-19-Associated Acute Respiratory Distress Syndrome

Observational study of thrombosis and bleeding in COVID-19 VV ECMO patients

When to consider lung transplantation for COVID-19

First lung and kidney multi-organ transplant following COVID-19 Infection

Lung Transplantation of COVID-19 Patients

Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis

Lung Transplantation Using a Hybrid Extracorporeal Membrane Oxygenation Circuit

Intraoperative management of a hybrid extracorporeal membrane oxygenation circuit for lung transplantation

Intraoperative extracorporeal membrane oxygenation and the possibility of postoperative prolongation improve survival in bilateral lung transplantation